13F filing recap · Q2 2017

What did Chou Associates buy in Q2 2017?

Reported stock-position changes between this filing and the previous one.

Stock value

$318.76M

Positions

Estimated turnover

12.3%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Increased positions

VRXValeant Pharmaceuticals International, Inc.$53.03Mreported value+700.0K shares+29.7%TEVATeva Pharmaceutical Industries Limited$16.84Mreported value+290.0K shares+134.9%

Reduced positions

CCitigroup Inc$20.81Mreported value-100.0K shares-24.4%NOKNokia Corp$7.73Mreported value-1.50M shares-54.5%